1. Home
  2. TPB vs BEAM Comparison

TPB vs BEAM Comparison

Compare TPB & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turning Point Brands Inc.

TPB

Turning Point Brands Inc.

HOLD

Current Price

$97.46

Market Cap

2.4B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.65

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPB
BEAM
Founded
1988
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Tobacco
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.7B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
TPB
BEAM
Price
$97.46
$27.65
Analyst Decision
Buy
Buy
Analyst Count
3
16
Target Price
$115.00
$49.13
AVG Volume (30 Days)
311.5K
1.6M
Earning Date
06-01-2026
05-15-2026
Dividend Yield
0.28%
N/A
EPS Growth
45.33
82.31
EPS
3.11
N/A
Revenue
$463,062,000.00
$24,000.00
Revenue This Year
$12.04
N/A
Revenue Next Year
N/A
$35.80
P/E Ratio
$34.48
N/A
Revenue Growth
28.39
33.33
52 Week Low
$51.48
$13.53
52 Week High
$146.90
$36.44

Technical Indicators

Market Signals
Indicator
TPB
BEAM
Relative Strength Index (RSI) 25.48 47.63
Support Level $96.69 $25.89
Resistance Level $107.85 $29.06
Average True Range (ATR) 6.36 1.91
MACD -4.47 -0.00
Stochastic Oscillator 1.00 23.03

Price Performance

Historical Comparison
TPB
BEAM

About TPB Turning Point Brands Inc.

Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: